ConforMIS posted 2Q17 revenue of US $18.5MM, -4.4% vs. 2Q16, and 1H17 revenue of $38.9MM, -1.6% vs. 1H16.
2Q17Â
2Q16Â
$ ChangeÂ
% ChangeÂ
 Joint Reconstruction Knees
$18.5Â
$19.3Â
-$0.8Â
-4.4%Â
1H17Â
1H16Â
$ ChangeÂ
% ChangeÂ
 Joint Reconstruction Knees
$38.9Â
$39.6Â
-$0.6Â
-1.6%Â
Performance highlights:
2Q17 product sales breakdown:
iTotal CR, iUni and iDuo $13.3MM, -15.6%
iTotal PS $4.8MM, +41.2% (full launch occurred in late 1Q16)
Growth affected by changes in field sales organization, reimbursement changes in Germany
Also noted an increase in payor denial of coverage from BlueCross/BlueShield and Cigna for CT imaging of the knee; critical because implant build relies on CT scan
Added a new Senior Vice President U.S. Sales, as well as Director of Marketing Communications and Demand Generation
Received FDA 510(k) clearance of iTotal Hip replacement system; has accelerated limited launch timing from 2019 to 2H18
After quarter’s close, entered into distribution agreement with IdealMed that more than doubles distribution personnel in the U.K. and Ireland
Decreased full-year guidance range to $75MM-$78MM, down from $80MM-$84MM
ConforMIS posted 2Q17 revenue of US $18.5MM, -4.4% vs. 2Q16, and 1H17 revenue of $38.9MM, -1.6% vs. 1H16.
Q17 2Q16 $ Change % ChangeÂ
 Joint Reconstruction Knees $18.5 $19.3 -$0.8 ...
ConforMIS posted 2Q17 revenue of US $18.5MM, -4.4% vs. 2Q16, and 1H17 revenue of $38.9MM, -1.6% vs. 1H16.
2Q17Â
2Q16Â
$ ChangeÂ
% ChangeÂ
 Joint Reconstruction Knees
$18.5Â
$19.3Â
-$0.8Â
-4.4%Â
1H17Â
1H16Â
$ ChangeÂ
% ChangeÂ
 Joint Reconstruction Knees
$38.9Â
$39.6Â
-$0.6Â
-1.6%Â
Performance highlights:
2Q17 product sales breakdown:
iTotal CR, iUni and iDuo $13.3MM, -15.6%
iTotal PS $4.8MM, +41.2% (full launch occurred in late 1Q16)
Growth affected by changes in field sales organization, reimbursement changes in Germany
Also noted an increase in payor denial of coverage from BlueCross/BlueShield and Cigna for CT imaging of the knee; critical because implant build relies on CT scan
Added a new Senior Vice President U.S. Sales, as well as Director of Marketing Communications and Demand Generation
Received FDA 510(k) clearance of iTotal Hip replacement system; has accelerated limited launch timing from 2019 to 2H18
After quarter’s close, entered into distribution agreement with IdealMed that more than doubles distribution personnel in the U.K. and Ireland
Decreased full-year guidance range to $75MM-$78MM, down from $80MM-$84MM
Copy to clipboard 
